About Bolt Biotherapeutics
Bolt Biotherapeutics is a company based in Redwood City (United States) founded in 2015 by Edgar Engleman. It operates as a HealthTech. Bolt Biotherapeutics has raised $177.49 million across 7 funding rounds from investors including RA Capital, Sofinnova and Rock Springs Capital. The company has 52 employees as of December 31, 2024. Bolt Biotherapeutics offers products and services including BDC-3042 and Boltbody™ ISAC Platform. Bolt Biotherapeutics operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Hummingbird Bioscience, among others.
- Headquarter Redwood City, United States
- Employees 52 as on 31 Dec, 2024
- Founders Edgar Engleman
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bolt Biotherapeutics, Inc.
-
Annual Revenue
$7.69 M (USD)-2.36as on Dec 31, 2024
-
Net Profit
-$63.12 M (USD)8.79as on Dec 31, 2024
-
EBITDA
-$66.06 M (USD)11.11as on Dec 31, 2024
-
Total Equity Funding
$177.49 M (USD)
in 7 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Jun 07, 2021
-
Investors
RA Capital
& 8 more
-
Employee Count
52
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bolt Biotherapeutics
Bolt Biotherapeutics is a publicly listed company on the NASDAQ with ticker symbol BOLT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Bolt Biotherapeutics
Bolt Biotherapeutics offers a comprehensive portfolio of products and services, including BDC-3042 and Boltbody™ ISAC Platform.
A Dectin-2 agonist antibody for cancer immunotherapy treatment.
Platform for immune-stimulating antibody conjugates targeting tumors.
People of Bolt Biotherapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Bolt Biotherapeutics
Bolt Biotherapeutics has successfully raised a total of $177.49M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bolt Biotherapeutics
Bolt Biotherapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Sofinnova and Rock Springs Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked |
Investor details for Bolt Biotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bolt Biotherapeutics
Investment portfolio details for Bolt Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bolt Biotherapeutics
Detailed financials for Bolt Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bolt Biotherapeutics Comparisons
Peer comparison for Bolt Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bolt Biotherapeutics
Bolt Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Hummingbird Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
Detailed competitors of Bolt Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bolt Biotherapeutics
Complete news archive for Bolt Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bolt Biotherapeutics
Bolt Biotherapeutics was founded in 2015.
Bolt Biotherapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Bolt Biotherapeutics is a funded company, having raised a total of $177.49M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Bolt Biotherapeutics is 52.
Annual revenue of Bolt Biotherapeutics is $7.69M as on Dec 31, 2024.
Bolt Biotherapeutics is engaged in pioneering cancer treatment through targeted immunotherapies. The company leverages the innate immune system, specifically myeloid cells, to create therapies that repolarize immune cells for tumor destruction. Solutions like BDC-3042 and the Boltbody ISAC platform are developed to address various cancer types. The approach integrates pattern recognition receptors to help the body identify tumor cells, while also activating the adaptive immune system. The focus is placed on innovative biotherapeutics within the healthcare sector.
Bolt Biotherapeutics's top competitors include Hummingbird Bioscience, Juno Therapeutics and Lyell Immunopharma.
Bolt Biotherapeutics offers BDC-3042 and Boltbody™ ISAC Platform.
Yes, Bolt Biotherapeutics is publicly traded on NASDAQ under the ticker symbol BOLT.
Bolt Biotherapeutics has 9 investors. Key investors include RA Capital, Sofinnova, Rock Springs Capital, Samsara BioCapital, and Vivo Capital.
The ticker symbol of Bolt Biotherapeutics is BOLT on NASDAQ.